US21 CFR21 CFR Part 528Secondary legislationIn force

Intentional Genomic Alterations in Animals

21 CFR Part 528 establishes regulatory pathways for intentional genomic alterations in animals, including rabbits producing recombinant human Factor VII in milk for hemophilia treatment, genetically modified Atlantic salmon with enhanced growth rates in contained freshwater facilities, pigs with CD163 gene deletion conferring PRRSV resistance, pigs with modified GGTA1 gene for use as food or therapeutic sources, and chickens producing human lysosomal acid lipase for medical treatment. Food and feed restrictions apply to certain lineages.

Last changed 2 months ago.

Extracted view for reading · Original for compliance evidence

PART 528—INTENTIONAL GENOMIC ALTERATIONS IN ANIMALS

§ 528.1080 Bc2371 recombinant deoxyribonucleic acid construct.

(a) Specifications and intended use. A single copy of Bc2371, a human Factor VII recombinant deoxyribonucleic acid (rDNA) gene construct, located on chromosome 3p1.1-2 in a diploid line (R69) of hemizygous and homozygous New Zealand white rabbits ( Oryctolagus cuniculus ).

(b) Sponsor. See No. 086047 in § 510.600 of this chapter.

(c) Conditions of use —(1) Intended use. The construct directs gene expression of recombinant human Factor VII (hFVII) in the mammary gland such that recombinant hFVII zymogen is present in the rabbit milk, enabling purification and activation of recombinant hFVIIa intended for the treatment of hemophilia A or B in humans with inhibitors to Factors VIII and IX.

(2) Limitations. Food or feed from R69 rabbits is not permitted in the food or feed supply.

§ 528.1092 opAFP-GHc2 recombinant deoxyribonucleic acid construct.

(a) Specifications. A single copy of the α-form of the opAFP-GHc2 recombinant deoxyribonucleic acid (rDNA) construct at the α-locus in the EO-1 α lineage of triploid, hemizygous, all-female Atlantic salmon ( Salmo salar ).

(b) Sponsor. See No. 086053 in § 510.600 of this chapter.

(c) Indications for use. Significantly more of these Atlantic salmon grow to at least 100 grams within 2,700 Celsius degree-days than their comparators.

(d) Limitations. These Atlantic salmon are produced as eyed-eggs and grown-out only in physically-contained, freshwater culture facilities specified in an FDA-approved application.

§ 528.2000 Deletion of exon 7 of CD163 gene in domestic pigs.

(a) Specifications. Deletion of one (heterozygous) or two (homozygous) copies of exon 7 of CD163 gene1(abbreviated CD163ΔE7) in domestic pigs ( Sus scrofa domesticus ).

(b) Sponsor. See No. 086205 in § 510.600(c) of this chapter.

(c) Conditions of use —(1) Intended use. Deletion of exon 7 of the CD163 gene in domestic pigs ( Sus scrofa domesticus) is intended to confer resistance to porcine reproductive and respiratory syndrome virus (PRRSV) in homozygous pigs. Pigs carrying one or two copies of CD163 D E7 , and their offspring, are intended for breeding or to be used as sources of food.

§ 528.2001 pPL657 recombinant deoxyribonucleic acid construct.

(a) Specifications. pPL657 in the glycoprotein galactosyltransferase alpha-1,3 ( GGTA1 ) gene in domestic pigs.

(b) Sponsor. See No. 086134 in § 510.600(c) of this chapter.

(c) Conditions of use —(1) Intended use. pPL657 rDNA construct in the glycoprotein galactosyltransferase alpha-1,3 gene ( GGTA1 ) in the lineage of domestic pigs ( Sus scrofa domesticus ) hemizygous and homozygous for the intentional genomic alteration resulting in undetectable endogenous galactose alpha-1,3-galactose sugar residues on biological derivatives of domestic pigs homozygous for the intentional genomic alteration lineage that are intended to be used as sources of food or human therapeutics including excipients, devices, drugs, or biological products.

(2) Limitations. Pigs of this lineage (possessing the intentional genomic alteration ( pPL657 rDNA construct)) should not be treated with aminoglycoside drugs and must only be housed in physically contained facilities specified in the approved application.

§ 528.2010 Human lysosomal acid lipase recombinant deoxyribonucleic acid construct.

(a) Specifications. A single copy of a human lysosomal acid lipase (hLAL) recombinant deoxyribonucleic acid (rDNA) gene construct located at the SYN LAL-C site in chromosome 6 in a specific, diploid line (SBC LAL-C) of hemizygous and homozygous domestic chickens ( Gallus gallus ), derived from the lineage progenitor XLL 109.

(b) Sponsor. See No. 069334 in § 510.600 of this chapter.

(c) Conditions of use —(1) Intended use. The gene construct directs the expression of that encoding gene such that recombinant, human lysosomal acid lipase (rhLAL) protein intended for the treatment of human disease is present in SBC LAL-C chicken egg whites.

(2) Limitations. Food or feed from XLL 109 chickens is not permitted in the food or feed supply.

Source

https://www.ecfr.gov/current/title-21/part-528

Canonical document at the regulator. Always cite this URL — not the Vantage detail page — in compliance evidence.

Related in United States

USEPAFR-2026-12544NewsIn force

No-Migration Variance From Land Disposal Restrictions for Clean Harbors Grassy Mountain, Utah

The Environmental Protection Agency (EPA) is approving with conditions, no-migration variances for four categories/groups of wastes, containing up to a combined 250 temporary disposal units ("put piles") at any one time, from the Resource Conservation and Recovery Act (RCRA) Land Disposal Restrictions (LDR) standards at Clean Harbors' Grassy Mountain (Clean Harbors) commercial treatment, storage and disposal facility (TSDF) in Tooele County, Utah. These variances will allow Clean Harbors to temporarily store treated hazardous wastes that are awaiting LDR compliance verification in put piles within its Subtitle C (hazardous waste) landfill. The petitioner demonstrated, to a reasonable degree of certainty, that there will be no migration of hazardous constituents from the put piles for as long as the wastes remain hazardous. Additionally, once LDR compliance is verified, the put piles will be disposed within the onsite RCRA hazardous waste landfill cell and will be subject to the conditions set out in the Compliance Monitoring Plan section of this document.

1 month ago
USEPAFR-2026-12564NewsIn force

Certain New Chemicals; Receipt and Status Information for February, March, and April 2026

This document announces the Agency's receipt of new chemical submissions under the Toxic Substances Control Act (TSCA), including information about the receipt of a Premanufacture Notice (PMN), Significant New Use Notice (SNUN), Microbial Commercial Activity Notice (MCAN), and an amendment to a previously submitted notice; test information; a biotechnology exemption application; an application for a test marketing exemption (TME); and a notice of commencement of manufacture (defined by statute to include import) (NOC) for a new chemical substance. This document also provides a periodic status report on the new chemical substances that are currently under EPA review or have recently concluded review. EPA is hereby providing notice of receipt of this information, as required by TSCA, and an opportunity to comment. This document covers new chemical submissions that have passed an initial screening and, for PMNs, SNUNs and MCANs, were determined to be complete during the period from 04/1/2026 to 04/ 30/2026 regardless of initial submission date.

1 month ago
US21 CFR21 CFR Part 17Secondary legislationIn force

Civil Money Penalties Hearings

21 CFR Part 17 establishes procedures for FDA administrative hearings on civil money penalties for violations of the Federal Food, Drug, and Cosmetic Act and Public Health Service Act. Penalties apply to violations involving prescription drug marketing, medical devices, pesticide residues, clinical trials, direct-to-consumer drug advertising, biologics, electronic products, mammography standards, vaccine record falsification, and tobacco products.

1 month ago
US21 CFR21 CFR Part 71Secondary legislationIn force

Color Additive Petitions

21 CFR Part 71 establishes the petition process for proposing color additives for use in foods, drugs, cosmetics, or human body coloring. Petitioners must submit detailed information including the additive's chemical identity, composition, physical and chemical properties, production methods, and safety data. Petitions require specification of intended uses, proposed conditions of use, and supporting toxicological and analytical data to demonstrate safety and suitability for FDA approval.

1 month ago
US21 CFR21 CFR Part 56Secondary legislationIn force

Institutional Review Boards

21 CFR Part 56 establishes standards for Institutional Review Boards (IRBs) that oversee clinical investigations of FDA-regulated products including drugs, medical devices, biological products, foods, dietary supplements, and electronic products. The regulation defines the composition, operation, and responsibilities of IRBs to protect the rights and welfare of human research subjects.

1 month ago